Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Naturally occurring inhibitors of cathepsins discovered at Sankyo

March 2, 1999

Agents for diabetes, impotence, lipid and cardiovascular disorders from Fujisawa

March 2, 1999

Lilly introduces new insulin dosing forms with improved convenience

March 1, 1999

Novo Nordisk discloses new potassium channel modulators and use in endocrine and other disorders

March 1, 1999

Schering-Plough initiates manufacture of Vasomax

March 1, 1999

Muse granted marketing approval in Germany

Feb. 26, 1999

Cortecs concludes phase III Macritonin trial

Feb. 26, 1999

Fujisawa's new hypoglycemic and hypolipidemic agents

Feb. 26, 1999

Azacycloalkane derivatives for diabetes and related disorders patented by Synthelabo

Feb. 26, 1999

Growth factors shown to improve muscle healing in animal models

Feb. 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...